CoChat

Resveratrol Derivatives as Potential Treatments for Alzheimer’s and Parkinson’s Disease

Open access
Arbo, Bruno Dutra, André-Miral, Corinne, Nasre-Nasser, Raif Gregorio, Schimith, Lúcia Emanueli, Santos, Michele Goulart, Costa-Silva, Dennis, Muccillo-Baisch, Ana Luiza, Hort, Mariana Appel · 2020 · Frontiers in Aging Neuroscience
Cited by 154

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Abstract

Neurodegenerative diseases are characterized by the progressive loss of neurons in different regions of the nervous system. Alzheimer's disease (AD) and Parkinson's disease (PD) are the two most prevalent neurodegenerative diseases, and the symptoms associated with these pathologies are closely related to the regions that are most affected by the process of neurodegeneration. Despite their high prevalence, currently, there is no cure or disease-modifying drugs for the treatment of these conditions. In the last decades, due to the need for the development of new treatments for neurodegenerative diseases, several authors have investigated the neuroprotective actions of naturally occurring molecules, such as resveratrol. Resveratrol is a stilbene found in several plants, including grapes, blueberries, raspberries, and peanuts. Studies have shown that resveratrol presents neuroprotective actions in experimental models of AD and PD, however, its clinical application is limited due to its rapid metabolism and low bioavailability. In this context, studies have proposed that structural changes in the resveratrol molecule, including glycosylation, alkylation, halogenation, hydroxylation, methylation, and prenylation could lead to the development of derivatives with enhanced bioavailability and pharmacological activity. Therefore, this review article aims to discuss how resveratrol derivatives could represent viable molecules in the search for new drugs for the treatment of AD and PD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fnagi.2020.00103

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Cited by

See all 154

Metadata

Authors
Arbo, B. D., André-Miral, C., Nasre-Nasser, R. G., Schimith, L. E., Santos, M. G., Costa-Silva, D., Muccillo-Baisch, A. L., & Hort, M. A.
Venue
Frontiers in Aging Neuroscience
Published
2020-04-17
Volume
12
Pages
103-103
ISSN
1663-4365 (ISSN-L)
OpenAlex
W3017152610
Cited by
154
References
23
FWCI
9.36
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Resveratrol Derivatives as Potential Treatments for Alzheimer’s and Parkinson’s Disease. https://app.cochat.ai/papers/10.3389/fnagi.2020.00103
The paper
Arbo, B. D., André-Miral, C., Nasre-Nasser, R. G., Schimith, L. E., Santos, M. G., Costa-Silva, D., Muccillo-Baisch, A. L., & Hort, M. A. (2020). Resveratrol Derivatives as Potential Treatments for Alzheimer’s and Parkinson’s Disease. Frontiers in Aging Neuroscience. https://doi.org/10.3389/fnagi.2020.00103

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.